Recombinant 60S ribosomal protein L27a (RPL27A)

What is RPL27A and what is its role in cellular machinery?

RPL27A (ribosomal protein L27a) is a component of the 60S large ribosomal subunit with a molecular weight of approximately 17 kDa . It belongs to the L15P family of ribosomal proteins and is primarily located in the cytoplasm . As part of the large ribonucleoprotein complex, RPL27A contributes to the fundamental process of protein synthesis in cells . The ribosome consists of a small 40S subunit and a large 60S subunit, together containing 4 RNA species and approximately 80 structurally distinct proteins, with RPL27A being one of the essential components of the 60S subunit .

What are the molecular characteristics of RPL27A?

The human RPL27A gene is located on chromosome 11p15.4 and consists of 5 exons . In Drosophila melanogaster, RPL27A consists of 149 amino acids with a precise molecular weight of 17,123 Daltons . The protein shows significant evolutionary conservation, with homology to rat and yeast L27a proteins and other members of the L15 ribosomal protein family . Interestingly, studies have identified that in Drosophila, RPL27A also shows homology with an invertebrate motor protein and a photoreceptor morphogenesis protein, suggesting potential multifunctional roles beyond protein synthesis .

How is RPL27A gene expression regulated?

RPL27A expression can be regulated at both transcriptional and post-transcriptional levels. Recent research has identified miR-595 as a microRNA that targets RPL27A . This miRNA is located within one of the commonly deleted regions identified for myelodysplastic syndrome (MDS) with monosomy 7 or isolated loss of 7q, suggesting a potential disease-relevant regulatory mechanism . Like other ribosomal proteins, multiple processed pseudogenes derived from the RPL27A gene are dispersed throughout the genome, which may contribute to complex regulatory patterns .

What antibodies and detection methods are available for studying RPL27A?

Several validated antibodies are available for RPL27A detection across multiple applications. Rabbit polyclonal antibodies have been successfully used for Western blot (WB), immunohistochemistry on paraffin-embedded tissues (IHC-P), and immunocytochemistry/immunofluorescence (ICC/IF) . For Western blotting, recommended dilutions typically range from 1:200 to 1:1000 . When performing immunohistochemistry, heat-mediated antigen retrieval with citrate buffer pH 6 is recommended before starting the IHC staining protocol . For immunofluorescence, antibodies at concentrations of approximately 2 μg/ml have been successfully used to label RPL27A in the cytosol and endoplasmic reticulum .

What methods are most effective for analyzing RPL27A expression at the mRNA level?

For quantifying RPL27A expression at the mRNA level, RNA extraction followed by quantitative real-time PCR (qPCR) is the most widely used approach. Total RNA can be extracted using commercial kits such as the RNeasy Mini kit (QIAGEN) . For qPCR, SYBR Green Master Mix has been effectively used to determine RPL27A expression levels . Human GAPDH is commonly used as an internal control gene, and relative expression levels can be calculated using the 2^-ΔΔCt method . This approach allows for accurate quantification of RPL27A transcript levels across different experimental conditions or patient samples.

What techniques are available for studying RPL27A protein interactions?

Co-immunoprecipitation assays have successfully demonstrated that endogenous RPL27A interacts with endogenous MDM2 and RPL5 in HCT-116 cells . For such studies, proteins are typically extracted using RIPA buffer supplemented with protease and phosphatase inhibitors . Primary antibodies against RPL27A (such as NBP2-38025 from Novus Biologicals) can be used for immunoprecipitation followed by Western blotting to detect interaction partners . Additionally, crystallographic studies have revealed interactions between RPL27A histidine hydroxylase (MINA53), Ni(II) and 2-oxoglutarate, providing structural insights into RPL27A modifications .

How is RPL27A involved in cancer development and progression?

RPL27A has been implicated in multiple cancer types with varying roles. In triple-negative breast cancer (TNBC), RPL27A appears to be critical for cancer development and metastasis, highlighting its potential as a therapeutic target . Variable expression patterns of RPL27A have been observed in colorectal cancers compared to adjacent normal tissues, although no direct correlation between expression levels and disease severity has been established . The mechanisms may involve RPL27A's interaction with the p53-MDM2 pathway, as knockdown studies have demonstrated activation of p53 and induction of apoptosis in various cancer cell lines .

What is the relationship between RPL27A and the p53 tumor suppressor pathway?

RPL27A plays a significant role in regulating the p53 pathway through interaction with MDM2. Experimental evidence shows that RPL27A knockdown reduces MDM2 expression at both transcriptional and post-transcriptional levels in multiple cell lines . This reduction in MDM2, a negative regulator of p53, leads to p53 activation and increased expression of downstream targets like p21 and Bax, ultimately resulting in cell cycle arrest and apoptosis . Co-immunoprecipitation studies have confirmed physical interaction between endogenous RPL27A, MDM2, and RPL5, supporting the involvement of RPL27A in the nucleolar stress response that activates p53 .

What is known about RPL27A's role in hematological disorders?

RPL27A has emerging significance in hematological disorders, particularly in myelodysplastic syndromes (MDS). Research has shown that RPL27A is a target of miR-595, which is located within commonly deleted regions in MDS patients with monosomy 7 or 7q deletions . Expression analysis has revealed that RPL27A is significantly upregulated in patients with -7/7q- karyotype compared to those with 5q deletions . Furthermore, knockdown of RPL27A in normal CD34+ cells reduced cell proliferation and induced p53 expression, suggesting its importance in normal hematopoiesis . Preliminary data indicates differential expression patterns between IPSS High Risk and Low Risk MDS patients, with potentially higher RPL27A expression in high-risk disease .

How can RPL27A knockdown models be effectively developed and validated?

Developing effective RPL27A knockdown models requires careful design and validation strategies. Short hairpin RNA (shRNA) approaches have been successfully employed, with constructs such as RPL27A-sh2 and RPL27A-sh4 showing different knockdown efficiencies . For optimal results, multiple shRNAs targeting different regions of the RPL27A transcript should be designed and tested to ensure specificity and efficacy. Validation of knockdown should include both mRNA quantification by qPCR and protein level assessment by Western blotting . Functional validation can include assessing effects on cell proliferation, cell cycle distribution, and apoptosis induction across different cell types to establish the biological significance of RPL27A depletion .

What structural and functional studies have been conducted on RPL27A?

Structural studies of RPL27A include crystallographic analysis of RPL27A histidine hydroxylase (MINA53) in complex with Ni(II) and 2-oxoglutarate (2OG) . This complex has been resolved at 2.78Å resolution using synchrotron radiation and single wavelength experimental methods . The crystal structure reveals important details about how RPL27A may be post-translationally modified. Functional studies have primarily focused on knockdown experiments in various cell lines and their effects on p53 activation, apoptosis, and cell proliferation . Additionally, hybridization studies in Drosophila have localized the RPL27A gene to chromosome 3R at 87F/88A, with a single mRNA of approximately 650 nucleotides .

How does RPL27A contribute to ribosome biogenesis and quality control?

As a component of the 60S ribosomal subunit, RPL27A plays an essential role in ribosome biogenesis. When RPL27A is depleted, it likely disrupts the normal assembly of the 60S subunit, triggering nucleolar stress responses . This stress response includes the release of free ribosomal proteins that can bind to and inhibit MDM2, leading to p53 stabilization . The quality control function of RPL27A may extend beyond simple structural roles, as evidenced by its interaction with other ribosomal proteins like RPL5 . These interactions suggest that RPL27A may participate in surveillance mechanisms that ensure properly assembled ribosomes, thereby preventing the production of defective proteins that could harm the cell.

How should researchers interpret changes in RPL27A expression across different experimental systems?

When interpreting changes in RPL27A expression, researchers should consider several key factors:

Research has shown that RPL27A knockdown in p53-null cells like K562 still induces some level of apoptosis (15-20%), albeit less than in p53-wild-type cells (up to 55%) , suggesting both p53-dependent and independent mechanisms.

What are the key considerations when studying RPL27A in patient samples?

Studying RPL27A in patient samples requires careful attention to several methodological aspects. First, appropriate control samples must be selected - for cancer studies, matched normal adjacent tissue provides the best comparison . For expression analysis, both mRNA (by qPCR) and protein levels (by immunohistochemistry or Western blotting) should be assessed, as post-transcriptional regulation may lead to discrepancies . Patient stratification based on clinical parameters is essential - for example, in MDS, patients should be grouped by cytogenetic abnormalities and risk categories . When interpreting results, researchers should consider that RPL27A expression may be influenced by treatment history, disease stage, and comorbidities, necessitating comprehensive clinical data collection.

How can researchers distinguish between direct and indirect effects of RPL27A modulation?

Distinguishing between direct and indirect effects of RPL27A modulation requires sophisticated experimental approaches:

• Time-course experiments can help identify primary (early) versus secondary (late) effects following RPL27A knockdown .

• Rescue experiments, where wild-type RPL27A is re-expressed in knockdown cells, can confirm specificity - direct effects should be reversed.

• Comparison across multiple cell lines with different genetic backgrounds can reveal context-dependent effects - for example, RPL27A-sh2 induced significant MDM2 reduction at both mRNA and protein levels in most cell lines but only at mRNA level in K562 cells .

• Correlation analysis between knockdown efficiency and phenotypic outcomes can establish dose-dependency - data shows that RPL27A-sh4 (inducing <50% knockdown) caused only 25% increase in apoptotic cells compared to RPL27A-sh2 (with stronger knockdown) causing 55% increase .

• Parallel studies with other ribosomal proteins like RPS14 and RPL5 can help identify ribosome-specific versus RPL27A-specific effects .